Intellectia LogoIntellectia
Product
Resources
Stock
Crypto
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategy
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns

Resources

Learn
Blog
Earnings
Tutorial
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
StockCryptoPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IKT
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
IKT
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

IKT Similar Chart Price Prediction

The price of IKT is predicted to go up -9.2%, based on the high correlation periods with EFSI. The similarity of these two price pattern on the periods is 95.18%.

stocks logo

IKT

stocks logo

EFSI

Down: -9.2%Similarity: 95.18%

IKT Revenue Forecast

IKT EPS Forecast

IKT FAQs

What is bull’s view on IKT?

IKT stock closed at $2.27 on January 31, 2025, with a strong regular market gain of +18.23%. Analysts are bullish, with Maxim Group and Jefferies maintaining Buy ratings and price targets of $8 and $5, respectively, driven by upcoming Phase 2 trial data for Parkinson’s disease and solid financial backing. The stock's recent momentum and positive sentiment suggest potential upside, but it remains speculative.

What is bear's view on IKT?

IKT stock currently trades at $2.24, significantly below analysts' price targets of $5.00 and $8.00. The bearish view stems from its high-risk nature as a clinical-stage biotech, with reliance on upcoming Phase 2 trial results for Parkinson’s disease and limited revenue generation. Despite a recent 53.25% six-month gain, the stock remains speculative without near-term catalysts.

IKT VS S&P500

Ask Intellectia about IKT

IKT Analyst's Forecast

Dennis Ding

Jefferies

Strong Buy

2024-11-08

Price Target

$8

Upside

+177.78%

Jefferies initiated coverage of Inhibikase Therapeutics with a Buy rating and $8 price target. The stock looks inexpensive as its novel imatinib oral pro-drug IkT-001Pro will enter Phase 2B for PAH, with an added free Parkinson's call option for oral risvodetinib, where expectations are super low, the analyst tells investors in a research note.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI Screener
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free

Hot Stocks

stocks logo

UCB

United Community Banks Inc

$32.23
1.74%
stocks logo

HHH

Howard Hughes Holdings Inc

$79.2
2.30%
stocks logo

GGB

Gerdau SA

$2.83
-2.75%
stocks logo

PJT

PJT Partners Inc

$159.26
1.21%
stocks logo

CVCO

Cavco Industries Inc

$524.98
1.34%
stocks logo

PBH

Prestige Consumer Healthcare Inc

$84.75
1.22%
stocks logo

M

Macy's Inc

$14.35
2.06%
stocks logo

MDU

MDU Resources Group Inc

$17.25
2.37%
stocks logo

FRO

Frontline Plc

$16.05
4.83%
stocks logo

NCNO

nCino Inc

$31.31
1.79%